Pharmaceutical / Drug Definition :
Inhibits conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; inactivates bradykinin and prostaglandins. Also increases plasma renin and potassium levels and reduces aldosterone levels, resulting in systemic vasodilation.
In the United States, Enalapril Maleate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Enalapril Maleate.
FDA Label Requirements and Exceptions
FDA Import Information
Enalapril Maleate (Enalapril Maleate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Enalapril Maleate (Enalapril Maleate Suppliers)
- Processors Enalapril Maleate
- Repackers Enalapril Maleate
- Relabelers Enalapril Maleate
- Exporters Enalapril Maleate
- Importers Enalapril Maleate
For more information about Enalapril Maleate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.